One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Editorial introductions
Varga, John; Ghirardello, Anna; Doria, Andrea; Gatto, Mariele; Kaplan, Mariana J.
doi : 10.1097/BOR.0000000000000751
Current Opinion in Rheumatology. 32(6):v-vii, November 2020.
Novel classifications for systemic sclerosis: challenging historical subsets to unlock new doors
Sobanski, Vincent; Lescoat, Alain; Launay, David
doi : 10.1097/BOR.0000000000000747
Current Opinion in Rheumatology. 32(6):463-471, November 2020.
Systemic sclerosis (SSc) is a severe rheumatic disease characterized by a considerable heterogeneity in clinical presentations and pathophysiological mechanisms.
Calcinosis: insights from other calcinoses
Tsakali, Sofia Serena; Shanahan, Catherine M.
doi : 10.1097/BOR.0000000000000746
Current Opinion in Rheumatology. 32(6):472-478, November 2020.
This review examines the current knowledge and recent developments in the field of vascular calcification focusing on the emerging role of senescence and inflammation in driving this disorder and exploring the overlap and relevance of these pathways to calcinosis in rheumatic disease.
Cancer and scleroderma: recent insights
Morrisroe, Kathleen; Nikpour, Mandana
doi : 10.1097/BOR.0000000000000755
Current Opinion in Rheumatology. 32(6):479-487, November 2020.
As survival in systemic sclerosis (SSc) improves, research interest has shifted to the leading cause of non-SSc-related death, namely cancer, which accounts for over a third of non-SSc-related deaths. This review will provide an overview of the recent insights into the evolving relationship between SSc and cancer.
The NADase enzyme CD38: an emerging pharmacological target for systemic sclerosis, systemic lupus erythematosus and rheumatoid arthritis
Peclat, Thais Ribeiro; Shi, Bo; Varga, John; Chini, Eduardo Nunes
doi : 10.1097/BOR.0000000000000737
Current Opinion in Rheumatology. 32(6):488-496, November 2020.
Here we review recent literature on the emerging role of nicotinamide adenine dinucleotide (NAD+) metabolism and its dysfunction via the enzyme CD38 in the pathogenesis of rheumatologic diseases. We evaluate the potential of targeting CD38 to ameliorate NAD+-related metabolic imbalance and tissue dysfunction in the treatment of systemic sclerosis (SSc), systemic lupus erythematous (SLE), and rheumatoid arthritis (RA).
Detection, screening, and classification of interstitial lung disease in patients with systemic sclerosis
Hoffmann-Vold, Anna-Maria; Molberg, ?yvind
doi : 10.1097/BOR.0000000000000741
Current Opinion in Rheumatology. 32(6):497-504, November 2020.
Interstitial lung disease (ILD) associates with disease burden and reduced life expectancy in systemic sclerosis (SSc). As ILD afflicts around 50% of SSc patients and is often present from early on, there is rationale for early and universal ILD screening. With the approval of the first SSc-ILD therapy last year, there is an increasing need for ILD classifications to assign the right treatment to the right patient. Here, we discuss recent advances on screening, detection, and classification of SSc-ILD.
Systemic sclerosis pathogenesis: contribution of recent advances in genetics
Orvain, Cindy; Assassi, Servin; Avouac, Jérôme; Allanore, Yannick
doi : 10.1097/BOR.0000000000000735
Current Opinion in Rheumatology. 32(6):505-514, November 2020.
To review susceptibility genes and how they could integrate in systemic sclerosis (SSc) pathophysiology providing insight and perspectives for innovative therapies.
Nonimmune mechanisms in idiopathic inflammatory myopathies
Loredo Martinez, Marta; Zampieri, Sandra; Franco, Chiara; Ghirardello, Anna; Doria, Andrea; Gatto, Mariele
doi : 10.1097/BOR.0000000000000748
Current Opinion in Rheumatology. 32(6):515-522, November 2020.
This review encompasses the main novelties regarding nonimmune mechanisms implicated in the pathogenesis of idiopathic inflammatory myopathies (IIM).
Up-to-date treatment and management of myositis
Pipitone, Nicol?; Salvarani, Carlo
doi : 10.1097/BOR.0000000000000745
Current Opinion in Rheumatology. 32(6):523-527, November 2020.
Myositis, or idiopathic inflammatory myopathy, is an overarching concept that includes dermatomyositis, polymyositis, immune-mediated necrotizing myopathy and the antisynthetase syndrome.
Cardiac involvement in inflammatory myopathies and inherited muscle diseases
Lilleker, James B.; Roberts, Mark; Diederichsen, Louise
doi : 10.1097/BOR.0000000000000753
Current Opinion in Rheumatology. 32(6):528-533, November 2020.
To examine recent developments relating to cardiac involvement in the adult idiopathic inflammatory myopathies (IIM) and those inherited muscle diseases which may present in adulthood and mimic IIM.
Cytokines and inflammatory mediators as promising markers of polymyositis/dermatomyositis
Cerezo, Lucie Andrés; Vencovsk?, Jir?; ?enolt, Ladislav
doi : 10.1097/BOR.0000000000000744
Current Opinion in Rheumatology. 32(6):534-541, November 2020.
Idiopathic inflammatory myopathies (IIMs), known also as myositis, represent challenging group of heterogeneous muscle disorders characterized by symmetric proximal muscle weakness and evidence of muscle inflammation.
Pathogenesis of inclusion body myositis
Greenberg, Steven A.
doi : 10.1097/BOR.0000000000000752
Current Opinion in Rheumatology. 32(6):542-547, November 2020.
To review the pathogenesis of inclusion body myositis (IBM).
Myositis autoantibodies: recent perspectives
Riddell, Victoria; Bagby, Stefan; McHugh, Neil
doi : 10.1097/BOR.0000000000000742
Current Opinion in Rheumatology. 32(6):548-552, November 2020.
To provide an overview of recent discoveries related to myositis-specific autoantibodies (MSAs) and assays used for their measurement.
Monitoring disease activity and damage in adult and juvenile idiopathic inflammatory myopathy
Gupta, Latika; Chinoy, Hector
doi : 10.1097/BOR.0000000000000749
Current Opinion in Rheumatology. 32(6):553-561, November 2020.
We have reviewed the literature to identify significant advances related to disease activity and damage in the idiopathic inflammatory myopathies (IIMs) from January 2019 to July 2020.
Immunometabolism in the pathogenesis of systemic lupus erythematosus: an update
Romo-Tena, Jorge; Kaplan, Mariana J.
doi : 10.1097/BOR.0000000000000738
Current Opinion in Rheumatology. 32(6):562-571, November 2020.
To provide an update on state-of-the-art evidence on the role of immunometabolism reprogramming in the pathogenesis of systemic lupus erythematosus (SLE).
Update on antimalarials and systemic lupus erythematosus
Ruiz-Irastorza, Guillermo; Mart?n-Iglesias, Daniel; Soto-Peleteiro, Adriana
doi : 10.1097/BOR.0000000000000743
Current Opinion in Rheumatology. 32(6):572-582, November 2020.
The purpose of this review is highlighting the most recent evidence on the clinical efficacy and toxicity of antimalarials in systemic lupus erythematosus (SLE).
Cutaneous and systemic connections in lupus
Maz, Mitra P.; Michelle Kahlenberg, J.
doi : 10.1097/BOR.0000000000000739
Current Opinion in Rheumatology. 32(6):583-589, November 2020.
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with multiple manifestations, with a majority of SLE patients having cutaneous involvement.
New classification criteria for systemic lupus erythematosus
Aringer, Martin; Petri, Michelle
doi : 10.1097/BOR.0000000000000740
Current Opinion in Rheumatology. 32(6):590-596, November 2020.
To compare the recently published European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for SLE with the Systemic Lupus International Collaborating Centers (SLICC) criteria and the earlier ACR criteria, focusing on their key concepts.
Biologic therapies for systemic lupus erythematosus: where are we now?
Murphy, Grainne; Isenberg, David A.
doi : 10.1097/BOR.0000000000000736
Current Opinion in Rheumatology. 32(6):597-608, November 2020.
Conventional approaches using hydroxychloroquine, corticosteroids and immunosuppressives have improved the prognosis for systemic lupus erythematosus (SLE) patients.
Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis
Narain, Sonali; Berman, Nicola; Furie, Richard
doi : 10.1097/BOR.0000000000000754
Current Opinion in Rheumatology. 32(6):609-616, November 2020.
It is an understatement to say that drug approvals in systemic lupus erythematosus (SLE), lupus nephritis, and Sjogren's syndrome have lagged far behind those in other autoimmune diseases, such as rheumatoid arthritis and psoriatic arthritis.
